Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Miller

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Human Gene Therapy Methods|October 24, 2018
Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) AntibodiesUma Kavita, Yanshan Dai, Lisa Salvador, et al.
Journal of General Internal Medicine|April 3, 2023
Evaluation of Implementation Strategies for Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Mindfulness-Based Stress Reduction (MBSR): a Systematic ReviewElizabeth S Goldsmith, Erin Koffel, Princess E Ackland, et al.
Journal of General Internal Medicine|April 10, 2023
What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA FacilitiesPrincess E Ackland, Marie E Kenny, Barbara A Clothier, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2004
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic propertiesKenneth J Valenzano, Wendy Miller, Zhengming Chen, et al.
Substance Use & Addiction Journal|September 6, 2025
Healthcare Expenditures Associated With Implementing an External Facilitation Program to Increase the Prescribing of Medications Used for the Treatment of Opioid Use Disorder Among VeteransAryan Esmaeili, Hildi J Hagedorn, Carla C Garcia, et al.
Implementation Science Communications|August 10, 2023
Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorderCarla C Garcia, Mark Bounthavong, Adam J Gordon, et al.
Journal of the American Medical Informatics Association : JAMIA|January 31, 2025
myAURA: a personalized health library for epilepsy management via knowledge graph sparsification and visualizationRion Brattig Correia, Jordan C Rozum, Leonard Cross, et al.
Neuropharmacology|April 9, 2005
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsyKenneth J Valenzano, Laykea Tafesse, Gary Lee, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Human Gene Therapy Methods|October 24, 2018
Development of a Chemiluminescent ELISA Method for the Detection of Total Anti-Adeno Associated Virus Serotype 9 (AAV9) AntibodiesUma Kavita, Yanshan Dai, Lisa Salvador, et al.
Journal of General Internal Medicine|April 3, 2023
Evaluation of Implementation Strategies for Cognitive Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Mindfulness-Based Stress Reduction (MBSR): a Systematic ReviewElizabeth S Goldsmith, Erin Koffel, Princess E Ackland, et al.
Journal of General Internal Medicine|April 10, 2023
What Contributes to Sustainability? Examining Access to Medications for Opioid Use Disorder in Low-Adopting VHA FacilitiesPrincess E Ackland, Marie E Kenny, Barbara A Clothier, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 1, 2004
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic propertiesKenneth J Valenzano, Wendy Miller, Zhengming Chen, et al.
Substance Use & Addiction Journal|September 6, 2025
Healthcare Expenditures Associated With Implementing an External Facilitation Program to Increase the Prescribing of Medications Used for the Treatment of Opioid Use Disorder Among VeteransAryan Esmaeili, Hildi J Hagedorn, Carla C Garcia, et al.
Implementation Science Communications|August 10, 2023
Costs of implementing a multi-site facilitation intervention to increase access to medication treatment for opioid use disorderCarla C Garcia, Mark Bounthavong, Adam J Gordon, et al.
Journal of the American Medical Informatics Association : JAMIA|January 31, 2025
myAURA: a personalized health library for epilepsy management via knowledge graph sparsification and visualizationRion Brattig Correia, Jordan C Rozum, Leonard Cross, et al.
Neuropharmacology|April 9, 2005
Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsyKenneth J Valenzano, Laykea Tafesse, Gary Lee, et al.
Pageof 3